RETRACTED ARTICLE: Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer.

Abstract

The main objective of this retrospective multicenter study, conducted by the Spanish Peritoneal Surgical Oncology Group (GECOP) was to analyze the survival outcomes of patients with stage IIIC serous epithelial ovarian cancer, after cytoreduction and intraoperative administration of hyperthermic intraperitoneal chemotherapy (HIPEC) with paclitaxel. Patients with stage IIIC serous epithelial ovarian cancer were recruited between May 2005 and October 2015, and treated by radical surgery using peritonectomy procedures, and HIPEC with paclitaxel. This multi-institutional retrospective study was carried out using a database containing prospectively collected parameters from five Spanish hospitals that were part of the GECOP. In total, 49 patients participated in the study. Complete cytoreduction (CC-0) was achieved in 38 patients (78%) and an optimal cytoreduction (CC-1) in the remaining 11 patients (22%). Following multivariate analysis, the presence of a Peritoneal Cancer Index (PCI) ≥ 20, and the impossibility of achieving a complete cytoreduction were independent factors associated with lower disease-free survival (DFS). The impossibility of achieving complete cytoreduction of disease, together with a PCI ≥ 14 were associated with an overall lower survival. Those patients with complete cytoreduction and who presented with a PCI < 14, reached a median DFS of 95months and an overall survival (OS) of 123months. HIPEC in patients with primary ovarian cancer is an alternative approach that requires serious evaluation for minimal residual disease treatment after complete cytoreduction.